VivoSeq
Other

Drooling

6

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Drooling is an early-stage landscape with 6 programs across 4 companies. The most active players are Vitae Pharmaceuticals Inc., an Allergan affiliate, Revance Therapeutics, Inc., Boehringer Ingelheim. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 2R

Revance Therapeutics, Inc.

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

2 programs

ApprovedC

Citius Pharmaceuticals, Inc.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Not yet recruiting1 · 33%

Clinical Trials

Trial Activity

Effect of Stellate Ganglion Block on Drooling in Parkinson's Syndrome
Not yet recruiting·—·N/A·NCT06370195·100 enrolled
Ipratropium Spray for Drooling Saliva in Parkinson's Disease
Completed·UUniversity Health Network, Toronto·Phase 2·NCT00296946·20 enrolled
A Clinical Study of Dihydroergotine Mesylate Extended-release Tablets for the Treatment of Drooling in Parkinson's Disease.
Completed·SSecond Affiliated Hospital of Soochow University·Phase 4·NCT06319118·120 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)